Trafalgar International (GCAN) Shares Outstanding (2016 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Shares Outstanding (Entity) of $944935.0 for Q1 2026, down 99.9% year-over-year from $974.9 million in Q1 2025, and up 14.54% quarter-over-quarter from $824984.0 in Q4 2025.
Trafalgar International (GCAN) Shares Outstanding (2016 - 2026) Analysis & Trends
Greater Cannabis Company's Shares Outstanding (Entity) history runs 11 years deep, the most recent figure standing at $944935.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) fell 99.9% year-over-year to $944935.0; the TTM figure through Mar 2026 stood at $944935.0 (down 99.9% YoY), while the FY2025 annual figure was $824984.0, down 99.9% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $944935.0, up from $824984.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.3 billion in Q2 2025, with the low at $824984.0 in Q4 2025.
- The 5-year median for Shares Outstanding (Entity) is $732.6 million (2023), against an average of $640.2 million.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) jumped 67.76% in 2025, then slumped 99.9% in 2026.
- Greater Cannabis Company's Shares Outstanding (Entity) stood at $587.8 million in 2022, then jumped by 36.9% to $804.6 million in 2023, then changed by 0.0% to $804.6 million in 2024, then tumbled by 99.9% to $824984.0 in 2025, then increased by 14.54% to $944935.0 in 2026.
- Business Quant data shows GCAN's Shares Outstanding (Entity) at $944935.0 in Q1 2026, $824984.0 in Q4 2025, and $900256.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 832.44 Mn |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | 944,935.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 944,935.00 |
| Dec 31, 2025 | 824,984.00 |
| Sep 30, 2025 | 900,256.00 |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | 910.37 Mn |
| Dec 31, 2024 | 804.64 Mn |
| Sep 30, 2024 | 804.64 Mn |
| Jun 30, 2024 | 804.64 Mn |
| Mar 31, 2024 | 732.64 Mn |
| Dec 31, 2023 | 755.15 Mn |
| Sep 30, 2023 | 766.68 Mn |
| Jun 30, 2023 | 732.64 Mn |
| Mar 31, 2023 | 732.64 Mn |
| Dec 31, 2022 | 587.77 Mn |
| Sep 30, 2022 | 617.92 Mn |
| Jun 30, 2022 | 516.97 Mn |
| Mar 31, 2022 | 508.64 Mn |
| Dec 31, 2021 | 489.50 Mn |
| Sep 30, 2021 | 492.98 Mn |
| Jun 30, 2021 | 478.64 Mn |